Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03310957
Title Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Seattle Genetics, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Ladiratuzumab vedotin + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.